Evidence map›Paper›PMID 37181357›Full record

ArticleFrontiers in medicine2023

Activation of the integrated stress response (ISR) pathways in response to Ref-1 inhibition in human pancreatic cancer and its tumor microenvironment.

Mahmut Mijit, Megan Boner, Ricardo A Cordova, Silpa Gampala, Eyram Kpenu, Angela J Klunk, Chi Zhang, MarK R Kelley, Kirk A Staschke, Melissa L Fishel

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Mahmut MijitDepartment of Pediatrics and Herman B Wells Center for Pediatric Research, Indianapolis, IN, United States.
Megan BonerDepartment of Pediatrics and Herman B Wells Center for Pediatric Research, Indianapolis, IN, United States.
Ricardo A CordovaIndiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, United States.
Silpa GampalaDepartment of Pediatrics and Herman B Wells Center for Pediatric Research, Indianapolis, IN, United States.
Eyram KpenuDepartment of Pediatrics and Herman B Wells Center for Pediatric Research, Indianapolis, IN, United States.
Angela J KlunkDepartment of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, United States.
Chi ZhangIndiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, United States.
MarK R KelleyDepartment of Pediatrics and Herman B Wells Center for Pediatric Research, Indianapolis, IN, United States.
Kirk A StaschkeIndiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, United States.
Melissa L FishelDepartment of Pediatrics and Herman B Wells Center for Pediatric Research, Indianapolis, IN, United States.
Indiana University Health · USIndiana University – Purdue University Indianapolis · USIndiana University School of Medicine

Funding

Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI David W Clapp · 1999 to 2026
$59.3M
Novel Role of Ref-1 in Pancreatic Cancer Etiology and ProgressionR01CA167291 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI FISHEL, MELISSA L., KELLEY, MARK R. · 2013 to 2022
$5.2M
Reprogramming PDAC Stroma by Targeting Coagulation in the Tumor MicroenvironmentU01CA274304 · NCI · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Melissa L. Fishel, Matthew J. Flick · 2022 to 2026
$4.6M
Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated ThrombosisU01HL143403 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FISHEL, MELISSA L., FLICK, MATTHEW J. · 2018 to 2022
$4.2M
(PQ9)Mechanistic Role of APE1 and BER in chemotherapy-induced peripheral neuropathyR01CA205166 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI FEHRENBACHER, JILL C, KELLEY, MARK R. · 2017 to 2021
$2.7M
Hyperglycemia mediated myeloproliferative diseaseR01HL140961 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI KAPUR, REUBEN · 2019 to 2022
$2.3M
(PQ12) Enhancement of DNA repair in neurons via a targeted APE1 small molecule modifier to decrease and reverse chemotherapy-induced peripheral neuropathy (CIPN)R01CA231267 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI FEHRENBACHER, JILL C, KELLEY, MARK R. · 2018 to 2022
$2.3M
Investigation of novel signaling protein in 3D and in vivo PDAC models using second generation Ref-1 inhibitorsR01CA254110 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI FISHEL, MELISSA L., HAN, BUMSOO · 2021 to 2025
$2.1M
A Fragment-Based Strategy for K-RAS Covalent InhibitorsR01CA264471 · NCI · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI MEROUEH, SAMY · 2021 to 2024
$1.9M
Targeting the Ref-1 signaling node for treating ocular neovascularizationR01EY031939 · NEI · INDIANA UNIVERSITY INDIANAPOLIS · PI CORSON, TIMOTHY W, KELLEY, MARK R. · 2020 to 2023
$1.7M
NCI NIH HHS P30 CA082709NCI NIH HHS R01 CA167291NCI NIH HHS R01 CA205166NCI NIH HHS R01 CA231267NCI NIH HHS R01 CA254110NCI NIH HHS R01 CA264471NCI NIH HHS U01 CA274304NEI NIH HHS R01 EY031939NHLBI NIH HHS R01 HL140961NHLBI NIH HHS U01 HL143403
6 · The paper itself

Abstract

Pancreatic cancer or pancreatic ductal adenocarcinoma (PDAC) is characterized by a profound inflammatory tumor microenvironment (TME) with high heterogeneity, metastatic propensity, and extreme hypoxia. The integrated stress response (ISR) pathway features a family of protein kinases that phosphorylate eukaryotic initiation factor 2 (eIF2) and regulate translation in response to diverse stress conditions, including hypoxia. We previously demonstrated that eIF2 signaling pathways were profoundly affected in response to Redox factor-1 (Ref-1) knockdown in human PDAC cells. Ref-1 is a dual function enzyme with activities of DNA repair and redox signaling, responds to cellular stress, and regulates survival pathways. The redox function of Ref-1 directly regulates multiple transcription factors including HIF-1α, STAT3, and NF-κB, which are highly active in the PDAC TME. However, the mechanistic details of the crosstalk between Ref-1 redox signaling and activation of ISR pathways are unclear. Following Ref-1 knockdown, induction of ISR was observed under normoxic conditions, while hypoxic conditions were sufficient to activate ISR irrespective of Ref-1 levels. Inhibition of Ref-1 redox activity increased expression of p-eIF2 and ATF4 transcriptional activity in a concentration-dependent manner in multiple human PDAC cell lines, and the effect on eIF2 phosphorylation was PERK-dependent. Treatment with PERK inhibitor, AMG-44 at high concentrations resulted in activation of the alternative ISR kinase, GCN2 and induced levels of p-eIF2 and ATF4 in both tumor cells and cancer-associated fibroblasts (CAFs). Combination treatment with inhibitors of Ref-1 and PERK enhanced cell killing effects in both human pancreatic cancer lines and CAFs in 3D co-culture, but only at high doses of PERK inhibitors. This effect was completely abrogated when Ref-1 inhibitors were used in combination with GCN2 inhibitor, GCN2iB. We demonstrate that targeting of Ref-1 redox signaling activates the ISR in multiple PDAC lines and that this activation of ISR is critical for inhibition of the growth of co-culture spheroids. Combination effects were only observed in physiologically relevant 3D co-cultures, suggesting that the model system utilized can greatly affect the outcome of these targeted agents. Inhibition of Ref-1 signaling induces cell death through ISR signaling pathways, and combination of Ref-1 redox signaling blockade with ISR activation could be a novel therapeutic strategy for PDAC treatment.

Indexed as

eIF2hypoxiaintegrated stress response (ISR)pancreatic ductal adenocarcinoma (PDAC)PERKredox signalingRef-1tumor microenvironment

Identifiers

PMID37181357
PMCPMC10174294
OpenAlexW4367183898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.